The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a type 2 diabetes treatment developed by Denmark-based Novo Nordisk (NYSE: NVO). Awiqli, the first and only weekly insulin preparation globally, marks a significant milestone as it was developed concurrently in China, the European Union, and the United States, with market filings initiated simultaneously. Prior to this, it has received approvals in the EU, Switzerland, Canada, and Australia.
Awiqli is a long-acting insulin analog that can reversibly bind to albumin, forming a reservoir within the circulatory system that allows for a slow and continuous release of the insulin. Over the course of a one-week interval between administrations, Awiqli provides a uniform distribution of hypoglycemic effects, with the insulin’s effects lasting for an entire week at clinically relevant doses.- Flcube.com
